samedan logo
 
 
 
spacer
home > ebr > spring 2008 > bridging vaccine translational research
PUBLICATIONS
European Biopharmaceutical Review

Bridging Vaccine Translational Research

Crawford Brown and Roger Lias of Eden Biodesign, Inc argue that in order for outsourced manufacturing strategies to work for vaccine development as they do for monoclonal antibodies, manufacturing development needs to account for the unique properties of vaccines

Interest in vaccines has never been greater, as shown by substantial high-profile private and public investment in the sector. For example, the market for vaccines for children and adolescents, is estimated to grow from $4.3 billion in 2006 to $16 billion by 2016 (1). Product development service providers, including contract manufacturing organisations (CMOs), can bridge vaccine translational research, enabling sponsors to rapidly develop and access new vaccines during early-stage clinical trials.

Many companies developing vaccines, unlike biotech companies developing monoclonal antibody products, need to make considerable capital investment in establishing their own manufacturing facilities, often at a time when capital is required to support clinical development. Table 1 shows a selection of top-tier biotechs that are developing vaccines and have established internal manufacturing capability.

This trend reflects, in part, the unique process and analytical challenges faced in developing each new vaccine, when compared to the platform approach that is more readily adopted for monoclonal antibody products (MABs). This article focuses on process design issues for the development of vaccines, comparing current commercial, technical and regulatory trends with the issues faced by companies developing highly characterised monoclonal antibodies.

RAPIDLY EXPANDING MARKET OPPORTUNITIES FOR BIOTECHS DEVELOPING VACCINES

The adage that ‘prevention is better than cure’ has been the basis for substantial interest in vaccines over the past few years from:

  • Governments
  • Pharmaceutical companies
  • Not-for-profit organisations

For governments struggling with rising healthcare costs, vaccines represent a cost-effective investment: for preventing illness; for government personnel rapidly mobilised for overseas operations; for use against pandemics, such as influenza; and more recently for preventing cancers caused by viral infections


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Dr Crawford Brown, Chief Executive Officer, co-founded Eden Biodesign, Inc in 2000 from Celltech-Medeva where he was Director of Product Development and was responsible for developing and manufacturing the biotech product pipeline. Among his achievements Crawford managed and led a successful pan-European submission for a complex recombinant vaccine which included an EMEA sponsored pre-approval inspection. Crawford has held senior technical management positions in both biotech and pharmaceutical companies and has been actively engaged in commercial biopharmaceutical development for over 20 years. As well as leading the company, he retains a major role in Eden Biodesign’s consultancy services.

Dr Roger Lias is President of Eden Biodesign, Inc and Group Commercial Director. Roger’s responsibilities include identifying and establishing strategic business partnerships and expanding Eden Biodesign’s offer to the large North American biopharmaceutical sector. Prior to joining Eden, Roger held the position of Vice President, Sales and Business Development at Cytovance Biologics. At KBI BioPharma, a start-up contract biomanufacturing company, he played an active role in securing funding, building revenues and was responsible for identifying and establishing strategic business partnerships and new business relationships. Prior to this, he was Vice President, Business Development, at Diosynth where he had global responsibility and headed North American sales and marketing for Lonza Biologics.

spacer
Dr Crawford Brown
spacer
spacer
spacer
Dr Roger Lias
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stoelzle pursues their path towards establishing sustainably long-term success

Being sustainably successful as an international enterprise for Stoelzle means acting responsibly, improving the working conditions and quality of life of our employees, as well as securing the opportunities of future generations. So we have a clear picture in mind when managing the company: our goal is to sustainably increase the value of the Stoelzle Glass Group from an ecological, social and economic perspective.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement